TrialMedical oncology (Northwood, London, England)2017

Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.

Silvia R Graziani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.